ITEM 7.01 REGULATION FD DISCLOSURE
On September 17, 2018, the Board of Directors (the “Board”) of Repro Med Systems, Inc. d/b/a RMS
Medical Products (the “Company”) formed a special committee of the Board (the “Special Committee”) with
authority to investigate, evaluate, make decisions, and take any and all action with respect to (a) a purported request (i) from
Andrew I. Sealfon, Dr. Paul M. Baker and Andrea Baker, in their capacities as shareholders of the Company, to call a special shareholders’
meeting and (ii) from Mr. Sealfon and Dr. Baker, in their capacities as directors of the Company, to call a special meeting of
the Board (collectively, the “Special Meetings Request”); and (b) issues of proper consideration for the Board raised
by certain discoveries involving Mr. Sealfon prior to his termination from the Company.
The Special Committee consists of all the Company’s current directors other than Mr. Sealfon and Dr.
Baker, each of whom has a conflicted interest with respect to the foregoing matters. The members of the Special Committee are Daniel
Goldberger, Joseph Manko, David Anderson, Arthur Radin and Mark Pastreich.
The Special Meetings Request states that the following matters are to be the subject of the special shareholders’
meeting: the removal of four directors (David Anderson, Daniel Goldberger, Joseph Manko and Arthur Radin), and the appointment
of two or four new directors, with prospective nominees to be named at or before the special shareholders’ meeting. The Special
Meetings Request also states that the following matters are to be the subject of the special meeting of the Board: the removal
of Daniel Goldberger from all positions with the Company, and the appointment of new individual(s) to replace Mr. Goldberger across
all positions. The Special Committee is currently evaluating the validity of the Special Meetings Request and has identified certain
deficiencies therein based upon its review of the Special Meetings Request to date.
Shortly following the termination of Mr. Sealfon’s employment and service as President, Chief Executive
Officer and Chairman of the Board, certain non-financial discoveries were made involving Mr. Sealfon prior to his termination from
the Company. On the advice of and through Company counsel, the Company engaged Kroll, a division of Duff & Phelps Corporation, to perform an independent investigation of certain
of Mr. Sealfon’s non-financial activities while employed by the Company. The Special Committee,
through counsel, will oversee Kroll with respect to this ongoing investigation.
The Special Committee has retained Olshan Frome Wolosky LLP for legal advice.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K,
shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference
into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such filing.